Coronary Vascular Function in Stable and Unstable Angina

  • Stefan H. J. Monnink
  • Hendrik Buikema
  • Ad J. van Boven
  • Wiek H. van Gilst
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 202)


Angina pectoris and acute myocardial infarction are the main cardiac manifestations of atherosclerosis. Atherosclerosis is a pathological condition that underlies several important disorders including coronary artery disease, cerebrovascular disease, and diseases of the aorta and peripheral arterial circulation. Since Edward Jenner first attributed angina pectoris to coronary artery disease in 1786, there is a growing understanding about the pathophysiology of coronary artery disease and its complications. The first coronary artery disease manifestation in women is more likely to be angina, whereas in men it more often presents as a myocardial infarction. Even after surviving the acute stage of myocardial infarction, the incidence of re- infarction, sudden death, angina pectoris and cardiac failure are all substantial. Further innovations in diagnosis and treatment of coronary disease will undoubtedly improve the outlook of patients surviving the initial attack.


Nitric Oxide Methylene Blue Endothelial Dysfunction Endothelial Function Balloon Angioplasty 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weitz Jl. Activation of blood coagulation by plaque rupture: mechanisms and prevention. Am J Cardiol 1995; 75:18B–22B.PubMedCrossRefGoogle Scholar
  2. 2.
    Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO 3rd. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995; 92:320–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Olsson RA, Bunger R. Metabolic control of coronary blood flow. Prog Cardiovasc Dis 1987; 29:369–87.PubMedCrossRefGoogle Scholar
  4. 4.
    Canty JM Jr, Schwartz JS. Nitric oxide mediates flow-dependent epicardial coronary vasodilation to changes in pulse frequency but not mean flow in conscious dogs. Circulation 1994; 89:375–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986; 250:H1145–9.PubMedGoogle Scholar
  6. 6.
    Vita JA, Treasure CB, Yeung AC, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992; 85:1390–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Vatner SF. Regulation of coronary resistance vessels and large coronary arteries. Am J Cardiol 1985; 56:16E–22E.PubMedCrossRefGoogle Scholar
  8. 8.
    Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 1983; 305:627–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Yasue H, Matsuyama K, Matsuyama K, Okumura K, Morikami Y, Ogawa H. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment. Possible role of early coronary atherosclerosis. Circulation 1990; 81:482–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Nobuyoshi M, Tanaka M, Nosaka H, et al. Progression of coronary atherosclerosis: is coronary spasm related to progression? J.Am.Coll.Cardiol. 1991; 18:904–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81:491–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995; 95:1747–55.PubMedCrossRefGoogle Scholar
  13. 13.
    Zeiher AM, Drexler H, Saurbier B, JustI H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92:652–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 1991; 69:1088–96.PubMedCrossRefGoogle Scholar
  15. 15.
    Drexler H, Hayoz D, Munzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69:1596–601.PubMedCrossRefGoogle Scholar
  16. 16.
    Treasure CB, Alexander RW. The dysfunctional endothelium in heart failure. J Am Coll Cardiol 1993; 22(4 Suppl A):129A–134A.PubMedCrossRefGoogle Scholar
  17. 17.
    Drexler H, Hornig B. Importance of endothelial function in chronic heart failure. J Cardiovasc Pharmacol 1996; 27 Suppl 2:S9–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Steinberg HO, Bayazeed B, Hook G, Johnson A, Cronin J, Baron AD. Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation 1997; 96:3287–93.PubMedCrossRefGoogle Scholar
  19. 19.
    Voors AA, Oosterga M, Buikema H, et al. Dyslipidemia and endothelium-dependent relaxation in internal mammary arteries used for coronary bypass surgery. Cardiovasc Res 1997; 34:568–74.PubMedCrossRefGoogle Scholar
  20. 20.
    Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338:1546–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91:2528–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie Kl, Bruschke AV. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation 1996; 94:1503–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors. A new trend. Circulation 1996; 94:240–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study [published erratum appears in: Circulation 1996; 94:1490]. Circulation 1996; 94:258–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Mulder P, Elfertak L, Richard V, et al. Peripheral artery structure and endothelial function in heart failure: effect of ACE inhibition. Am J Physiol 1996; 271:H469–77.PubMedGoogle Scholar
  27. 27.
    Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. JAMA 1997; 277:715–21.Google Scholar
  28. 28.
    Fischman DL, Leon MB, Bairn DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331:496–501.Google Scholar
  29. 29.
    Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489–95.PubMedCrossRefGoogle Scholar
  30. 30.
    Serruys PW, Emanuelsson HU, van der Giessen W, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation 1996; 93:412–22.PubMedCrossRefGoogle Scholar
  31. 31.
    Bertrand ME, Lablanche JM, Fourrier JL, Gommeaux A, Ruel M. Relation to restenosis after percutaneous transluminal coronary angioplasty to vasomotion of the dilated coronary arterial segment. Am J Cardiol 1989; 63:277–81.PubMedCrossRefGoogle Scholar
  32. 31.
    El Tamimi H, Davies GJ, Crea F, Maseri A. Response of human coronary arteries to acetylcholine after injury by coronary angioplasty. J Am Coll Cardiol 1993; 21:1152–7.CrossRefGoogle Scholar
  33. 33.
    Weidinger FF, McLenachan JM, Cybulsky Ml, et al. Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery. Circulation 1990; 81:1667–79.PubMedCrossRefGoogle Scholar
  34. 34.
    Jenkins JS, Webel R, Laughlin MH, et al. The effects of intravascular stents on vasomotion in porcine coronary arteries. J Invasive Cardiol 1995; 7:200–6.PubMedGoogle Scholar
  35. 35.
    Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Vanhoutte PM, Eber B. Endothelium-derived relaxing and contracting factors. Wien Klin Wochenschr 1991; 103:405–11.PubMedGoogle Scholar
  37. 37.
    Vanhoutte PM. Serotonin, hypertension and vascular disease. Neth Med 1991; 38:35–42.Google Scholar
  38. 38.
    Caramori PR, Lima VC, Seidelin PH, Newton GE, Adelman AG. Endothelial dysfunction distal to stents implanted for more than six months [abstract]. Circulation 1997; 96(8 Suppl):1756.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Stefan H. J. Monnink
  • Hendrik Buikema
  • Ad J. van Boven
  • Wiek H. van Gilst

There are no affiliations available

Personalised recommendations